HCC represents the second most common cause of cancer-related death worldwide 1 . HCC occurs almost exclusively in patients with liver cirrhosis 2 , thus underlying the important roles of the proinflammatory, angiogenic and profibrotic microenvironment in the cirrhotic liver for hepatocarcinogenesis 3,4 . The degree of liver fibrosis also affects the feasibility and efficacy of systemic therapies because of impaired drug delivery, altered metabolism, liver dysfunction and changes in hepatic perfusion 5, 6 . In addition, fibrosis and cirrhosis modulate the interactions between cancer cells and extracellular matrix in HCC. Finally, the response of cancer and stromal cells-e.g., tumor-associated macrophages or cancer-associated fibroblasts-to pharmacologic agents is likely to be different in cirrhotic livers compared with that in healthy livers or subcutaneous space because of different local cues and cell origins 7 . As most cases of HCC (~80%) develop in a cirrhotic liver, current staging algorithms for HCC 8 acknowledge the important prognostic role of the severity of liver cirrhosis and the impact of the underlying liver disease on the efficacy and safety of current treatments. Thus, the severity of underlying fibrosis influences treatment decisions in patients with HCC, and this is reflected by current practice guidelines 9 . Nevertheless, the mechanisms by which the proinflammatory and profibrotic liver microenvironment regulate HCC growth and progression or affect HCC response to systemic therapy remain poorly understood 4 . In part, this is due to a paucity of in vivo models for studying HCC occurring with underlying liver cirrhosis. Thus, clinically relevant animal models of HCC recapitulating the pathologic microenvironment of the cirrhotic liver are required to promote the development of novel systemic therapies 10 . We have developed a syngeneic, orthotopic model of HCC in immunocompetent mice with underlying liver cirrhosis 7, 11 . This model is potentially useful for studying various biological aspects of HCC, including cancer cell proliferation, apoptosis, epigenetics, metabolism, treatment resistance, angiogenesis, metastasis, tumor microenvironment and efficacy of novel therapeutic approaches.
Carcinogen-induced models. In other models, HCC is induced in immunocompetent mice using carcinogens-such as diethylnitrosamine (DEN)-to overcome the limitation of immunodeficiency and lack of heterogeneity. However, the time to tumor formation and tumor sizes can vary substantially depending on the mouse strain, and often multiple tumor lesions may develop. Thus, chemically induced models are difficult to standardize, which results in difficulties in designing and performing experiments, particularly for testing the therapeutic efficacy of new agents. Most importantly, none of these models recapitulates the pathological host environment of a cirrhotic liver that is present in most cases of human HCCs.
Transgenic models. Transgenic models or GEMs of HCC are widely considered the state of the art. They include hepatocytespecific models (using the albumin promoter) of Myc (also known as c-Myc) 14 and astrocyte-elevated gene-1 (officially known as Mtdh, also known as AEG-1) 15 . In GEMs with dual (albumindriven) Mtdh and Myc overexpression, mice developed aggressive HCCs, as well as lung metastases 16 . Moreover, diethylnitrosamine treatment substantially accelerated hepatocarcinogenesis in albumin promoter-driven Mtdh/Myc-overexpressing mice 16 .
CRISPR-Cas models. Another novel technique to induce HCC tumors in wild-type mice uses hydrodynamic injections of clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins. This CRISPR-Cas technology delivers single-guide RNAs to target tumor-suppressor genes (such as Pten or Trp53 (also known as p53)) or the Ctnnb1 oncogene. This technique enables direct mutations of tumor suppressors or oncogenes in order to study functional genomics in HCC. Stauffer et al. 17 showed that coactivation of AKT and β-catenin in mice rapidly induces the formation of lipogenic liver tumors. These authors used hydrodynamic injections to deliver activated AKT and β-catenin for the initiation of hepatocarcinogenesis. This model resulted in hepatic adenomas, and after in vivo passage these adenoma cells formed α-fetoprotein-and CD133-expressing HCC tumors. This mouse HCC model was developed from the steatotic-neoplastic transformation of hepatocytes, which mimics the microenvironment in human diet-induced or metabolic-induced HCC in patients with fatty liver disease. This model of HCC in steatotic liver is a reproducible and rapid transgenic model that provides insights into the intrinsic molecular mechanism involved in early tumorigenesis. However, it lacks pronounced fibrosis that is found in human nonalcoholic steatohepatitis (NASH) cirrhosis, in which HCC tumors usually follow the sequential development of hepatic steatosis, inflammatory fatty liver disease, fibrosis and NASH cirrhosis, and HCC. Thus, this model recapitulates human HCC in a noncirrhotic fatty liver disease background.
Adenovirus models. Another hepatocyte-specific HCC model induces oncogenic simian vacuolating virus 40 (SV40) large T antigen via adenovirus transfer, and this model has been used to investigate antigen-specific tolerance 18 .
Metabolic models. Finally, Wolf et al. 19 showed that metabolic activation of intrahepatic CD8 + T cells and natural killer (NK) T cells causes NASH and eventually HCC. HCC was established after 12 months of long-term exposure to a choline-deficient high-fat diet.
Although all these elegant models recapitulate spontaneous carcinogenesis, the mice show only mild fibrosis and do not display underlying liver cirrhosis. Although concomitant administration of CCl 4 or thioacetamide might be feasible in these models to create a cirrhotic background, this remains to be demonstrated.
Experimental design
Here we describe a protocol for developing preclinical mouse models of orthotopic HCC in mice with underlying liver cirrhosis. This model can be established using implantation of syngeneic mouse HCC cell lines or by induction of hepatocarcinogenesis in GEMs, such as Stk4 −/− Stk3 F/− mice 7, 20 . This GEM is a model of yes-associated protein 1 (Yap1) oncogene-driven carcinogenesis, which is a relevant driver of HCC 21, 22 . Both strains of mice used in this protocol-C3H mice and Stk4 −/− Stk3 F/− mice-have intact immune systems, which allows studies of immune responses in HCC 11, 23 . The setting of carcinogenesis within a cirrhotic liver tissue provides a clinically relevant model, which recapitulates key features of human HCC progression 7, 11 . Thus, these models provide a unique platform to study HCC-stroma interactions and to perform treatment efficacy studies in an inducible and reproducible model of HCC 7, 11 .
The rationale for developing and using this orthotopic mouse HCC model in fibrotic liver is based on previous studies from our laboratory, and those of others, which have demonstrated an important role for tumor stroma in HCC and other tumors 3, 7, 10, 11 . Previous studies have revealed that inflammatory cells, integrin signaling, growth factor secretion and interactions, and communication between activated hepatic stellate cells and tumor cells in a fibrotic tumor microenvironment all contribute to tumor progression in HCC 24, 25 . As discussed in the following section, the protocol can be used to establish clinically relevant mouse HCC models for various experimental studies. The protocol includes three main sections: induction of liver fibrosis/ cirrhosis in the liver of C3H mice (Steps 1-10); HCC tumor cell implantation in the fibrotic/cirrhotic liver of C3H mice Strains of mice. C3H mice and Stk4 −/− Stk3 F/− mice should be kept under pathogen-free conditions to maintain overall health of mice, to control diseases and to prevent infection outbreak. Our group developed and described Stk4 −/− Stk3 F/− mice; see Zhou et al. 20 . Alternatively, mice with double-floxed mutations of both Stk4 and Stk3 in hepatocytes have been developed, and they are available from Jackson Laboratory (stock no. 017635; ref. 26) . During fibrosis induction (CCl 4 administration), after Cre-adenovirus injection and after orthotopic tumor implantation, mice should be monitored daily for signs of illness by measuring body weight and by checking general condition and vital signs. Small-animal ultrasound can be used to noninvasively monitor HCC tumor uptake and growth in the liver longitudinally over time (Supplementary Fig. 1 ). All animals must receive humane care according to the criteria outlined in the US National Institutes of Health (NIH) guide for the care and use of laboratory animals 27 . Tumors derived from mouse HCC cell injections into livers are established as a syngeneic mouse model 7-10 d after implantation. The HCC tumor uptake rate can vary by tumor cell line and mouse strain used. The mouse HCA-1 cell line consistently establishes hepatic tumors in >95% of implanted C3H mice 7, 11 .
Considerations for sample calculation and control groups. It is important to plan your experiment in order to obtain a sufficient number of mice per group, especially if your expected difference in the respective readout (e.g., tumor size) is small.
A sample calculation for a typical treatment testing in the cirrhotic HCA-1 model is as follows:
An experimental group size that usually allows the detection of potential statistically differences in tumor size between different treatments is n = 8 mice per group. For example, there are three treatment groups: control group treated with vehicle or placebo, standard therapy (e.g., sorafenib) and experimental therapy.
• Consider a potential dropout rate during fibrosis induction (usually <2% in male C3H mice, but it is better to calculate it at a conservative rate of 5%). Consider an HCA-1 tumor uptake rate of 90% in orthotopic graft. In this case, 8 mice × 3 groups × 1.05 (5% dropout during fibrosis induction) × 1.10 (90% tumor uptake rate) = 28 mice.
A sample calculation for a typical experiment for the cirrhotic Stk4/Stk3-mutant model is as follows:
An experimental group size that usually allows the detection of potential statistically differences in tumor size between different treatments is n = 8 mice per group. For example, there are three treatment groups: control group treated with vehicle or placebo, standard therapy (e.g., sorafenib) and experimental therapy. Consider a potential dropout rate during fibrosis induction (up to 5% in Stk4/Stk3-mutant mice). Stk4/Stk3-mutant HCC tumor incidence rate after successful adeno-Cre tail-vein injection is 100%. In this case, 8 mice × 3 groups × 1.05 (5% dropout during fibrosis induction) = 26 mice. Considerations about costs and time effort. The models described in this protocol have a high cost in terms of reagents and surgical expertise, and they require long induction timesCCl 4 administration to induce fibrosis takes 12 weeks and adenoCre injections for HCC formation take 8 weeks. Together with a typical treatment-testing period of 3-4 weeks, the timeline for an experiment could extend up to 5-6 months. Cost calculations for these models must thus also consider animal housing during this time frame. In addition, the time effort and expertise needed for animal handling and surgery must be considered.
Mouse HCC cell lines. Various human HCC cancer cell lines have been established for the development of xenograft models in immunodeficient mice. However, few cell lines are available for syngeneic mice. The illustrative data that we show here use the C3H mouse-derived HCC cell line HCA-1 to establish the orthotopic HCC model 7, 11 . HCA-1 cells were cultured using DMEM culture medium supplemented with 10% (vol/vol) FBS, and they were regularly checked for mycoplasma contamination to avoid artificial results from animal infection. In general, a single intrahepatic implantation of 1 × 10 6 HCA-1 cells is sufficient to result in tumor formation in C3H mice.
Induction of liver fibrosis or cirrhosis in mice (Steps 1-10).
Liver cirrhosis results from repeated liver damage and chronic inflammation, which leads to the massive deposition of extracellular matrix (mainly collagen) and the formation of scar tissue (septa) in the liver. 
Orthotopic tumor implantation in cirrhotic livers (Steps 32-35).
HCA-1 cells are directly implanted in C3H mice with liver cirrhosis induced by 12 weeks of CCl 4 treatment ( Figs. 1 and 3) . Small-volume suspensions containing HCA-1 cells and Matrigel are injected into the subcapsular region of the liver parenchyma in the median lobe. Typically, we suspend 10,000,000 cells in 200 µl of serum-free medium. Directly before injection, we mix the cell suspension at a 1:1 (vol/vol) ratio with Matrigel in a small tube to increase the viscosity of the injected cell suspension. Small 0.5-ml syringes with 28.5-gauge needles are used to inject the cell/Matrigel suspension. To avoid leakage of tumor cells from the injection site-which might lead to local spread and 'seeding' metastasis in the peritoneal cavity-we limit the injected volume to 20-30 µl. A steady and slow injection should be performed to prevent leakage of the injected cell suspension and to minimize the damage of the surrounding liver tissue. After removal of the needle, the liver surface at the site of needle tract should be covered with Gelfoam for 5 min to minimize bleeding and potential backflow/leakage.
Alternative approaches to intrahepatic cancer cell implantation. Lee et al. 29 have described a percutaneous ultrasound-guided approach to inoculate Vx-2 carcinoma cells in the liver of rabbits. This technique resulted in a high success rate (100%) and was less invasive than an open laparotomy method. However, tumor seeding occurred more often (20.8%) in the ultrasound-guided approach than in their laparotomy controls (8.3%). In addition, there was thoracoabdominal cancer cell seeding in 20.8% of cases, and also in the peritoneal cavity in 8.3% of the cases 29 . A percutaneous technique has been previously described for the inoculation of human hepatocytes in immunodeficient mice 30 . However, although an ultrasoundguided (less invasive) approach might also be possible for cancer cell inoculation in mice, it carries the important risk of peritoneal seeding at the time of inoculation, which could compromise the experiment. Alternative approaches to induce liver fibrosis or cirrhosis in mice. Common alternative methods to induce liver fibrosis and cirrhosis in mice include the following: (i) common bile duct ligation (CBDL), a surgical model of secondary biliary cirrhosis in which the common bile duct is double ligated and resected, thus causing secondary biliary cirrhosis after 5-8 weeks; and (ii) chronic thioacetamide (TAA) administration, usually injected intraperitoneally twice or three times a week. It is noteworthy that the CBDL cirrhosis model is associated with high morbidity, and thus it might be difficult to use it in conjunction with additional interventions such as orthotopic tumor cell implantation surgery and long-term drug treatments in mice.
Cirrhosis induction in the Stk4
Monitoring orthotopic liver tumor growth in mice. The orthotopic nature of this model does not allow direct monitoring of tumor growth or size. Besides ultrasound, which is described in this protocol, there are other imaging options such as microcomputerized tomography (microCT) or MRI that could be used for this purpose if expertise and resources are available. An inexpensive but invasive alternative is to surgically open the abdomen of mice at predefined time points to directly measure the tumor size. However, repetitive surgeries could confound the experimental outcomes. Another method for monitoring tumor growth for grafted tumors is to use prior transfection of cancer cells with luciferase (Gaussia luciferase or firefly luciferase). Although feasible, this method could also confound the results by introducing changes in cancer cells' phenotype 31 , and it is restricted to implanted tumor models. In summary, for longitudinal evaluation of tumor growth in this model, we recommend an ultrasound device equipped with specific probes for small-animal imaging. Below, we provide a detailed step-by-step protocol that can serve as a research tool to examine the interaction between HCC cancer cells and the fibrotic microenvironment in a cirrhotic liver. This protocol produces clinically relevant animal models for HCC. Furthermore, these models can also be used for preclinical drug testing in HCC. Scale (capable of measuring mouse weight) Syringe, 1 ml (BD, no. 309659) Gavage needle with a ball tip  crItIcal Gauge size and needle length should be determined on the basis of the size and weight of the animals.
MaterIals

REAGENTS
•
For gavaging of male C3H or Stk4 −/− Stk3 F/− mice starting at the age of 4-5 weeks and a total exposure period of 12 weeks thereafter, we recommend using a 20-gauge (1-1.5 inches) gavage needle.
Surgical supplies (orthotopic hepatocellular carcinoma cell implantation)
Syringe  crItIcal step For longer periods of administration (i.e., 12 weeks), we recommend oral gavage of CCl 4 /olive oil because it is better tolerated by mice, and it leads to reproducible effects on liver histology. In addition, corn oil and/or olive oil are associated with peritoneal irritation and potential adhesions-which might complicate surgical implantation of HCC cells.
2| Draw 150 µl of CCl 4 20% (vol/vol) gavage solution (or olive oil as vehicle for control groups) into a 1-ml syringe with the gavage needle. ! cautIon Avoid the formation of air bubbles while drawing the gavage solution to ensure administration of the right volume.  crItIcal step The gavage procedure should be performed by well-trained personnel.  crItIcal step Gavaging needles that are adequate for the size and weight of the mice must be used.
3|
Tightly hold the mouse in a vertical position. Place the body of the mouse straight and extend the head.  crItIcal step Ensure that the position of the mouse is secured before inserting the gavage needle.
4|
Insert the gavage needle gently into the mouth of the mouse and search for a position that can allow the needle to bypass the tongue. 
5|
8|
Put the mice back to the original cage with the regular diets, and monitor the recovery of the mice. If any sign of labored breathing or respiratory distress is observed, use CO 2 inhalation to euthanize the mice.
9|
Continue the administration of the CCl 4 20% (vol/vol) gavage solution (or olive oil as vehicle for control groups) three times per week for 12 weeks. Closely monitor the health condition of the mice. ? trouBlesHootInG 10| Twelve weeks after the first gavage, proceed to the next step to orthotopically implant HCC cells in the cirrhotic liver.  crItIcal step When you establish the cirrhotic HCC model for the first time, include an additional subgroup of mice in order to confirm the cirrhotic state of the liver. Euthanize these mice using CO 2 inhalation, collect the livers and fix them in 4% (wt/vol) PFA solution. After embedding in paraffin, slice the paraffin block, mount the slices on glass slides and perform H&E staining to assess necroinflammation and fibrosis, Masson's trichrome staining to assess extracellular matrix fraction or Sirius red staining to assess fibrillar collagen content.
Generation of orthotopic syngeneic Hcc tumors in mice with liver fibrosis
• tIMInG 3 h 11| Twelve weeks after the first gavage, stop the treatment of CCl 4 20% (vol/vol) gavage solution (or olive oil).
12|
Two to 3 d after the last CCl 4 treatment, weigh and prepare the mice for the following procedure.
13| Prewarm PBS and DMEM culture medium in a 37 °C water bath before use. Prewarm trypsin at room temperature.
14|
Remove the medium from the dish containing HCA-1 cells at 80% confluence.  crItIcal step Avoid using antibiotics to culture cells at least 2 weeks before this step.  crItIcal step Avoid cell passaging for at least 2 d before this step.
15|
Gently rinse the dish with prewarmed PBS (10 ml per 10-cm 2 dish) and aspirate the PBS afterward.
16| Add 2 ml of 1× trypsin-EDTA (0.05% (wt/vol) to the dish. Gently shake the dish to ensure full coverage of the surface area by the trypsin solution. Put the plates in the 37 °C incubator.
17| After 3-5 min, observe the attached cells on the plate by using a bright-field microscope. Gently tap the dish to facilitate cell detachment.  crItIcal step Do not leave the cells in the trypsin solution for more than 5 min. ? trouBlesHootInG
18|
When the majority of HCA-1 cells are detached, add 8 ml of DMEM medium to neutralize the trypsin in the dish. Gently resuspend and mix the HCC cell suspension. Collect the cells in a 15-ml centrifuge tube.
19| Centrifuge the HCC cell suspension in the 15-ml centrifuge tube for 5 min at 200-250g at room temperature. Wash the cells with 10 ml of PBS. Centrifuge the cells for 5 min at 200-250g at room temperature and resuspend the cells in serum-free DMEM medium.
20|
Use a cell counter to determine the cell number. Adjust the cell concentration to 10 6 cells per 10 µl in Matrigel (corresponding to the final tumor cell inoculum per injected volume) with serum-free medium. Keep the cell suspension on wet ice.
21|
Place the Matrigel solution on wet ice.
22|
Anesthetize the mice by using ketamine (100 mg/ml)/xylazine (10 mg/ml) mixture. Use a dose of 10-12 µl/g body weight (corresponding to a dose of 100-120 mg/kg of ketamine and 10-12 mg/kg of xylazine).
23|
After anesthesia, place and keep the mice on a heating pad to avoid hypothermia.
24|
Shave the abdominal region of the mouse and place the mouse in a supine position.
25|
Use sterile gauzes soaked in 70% (vol/vol) ethanol to disinfect and clean the shaved abdominal region from any leftover hair.
26|
Gently grab the skin with a forceps and perform a midline abdominal incision of the skin (starting ~1 cm under the xyphoid process).
27|
Identify the linea alba in the midline of the abdominal muscle layer and perform a similar incision of 1 cm along the linea alba.
28|
Expose the median lobe of the liver by using a sterile cotton swab soaked in sterile saline solution.
? trouBlesHootInG 29| Put a small piece of sterile Gelfoam (0.5 × 0.5 cm) on the exposed liver to maintain the liver surface moisture.
30|
Immediately before orthotopic implantation (when the liver is already exposed), the HCC cell suspension should be mixed with Matrigel ( 36| Prevent leakage by placing a sterile Gelfoam for 5 min on the needle track.
37|
Remove the sterile Gelfoam and assess the liver surface at the needle track for leakage and bleeding.
38|
Gently wash the injection site with sterile saline solution using a 1-ml syringe with a 25-gauge needle.
39|
Close the muscle layer of the abdominal wall by a continuous suture using Ethibond suture 5-0.
40|
Close the skin layer of the abdominal wall by placing two or three 9-mm autoclips using the autoclip applier.
41|
Leave the mouse on the heating pad and allow the mouse to recover from anesthesia.
42|
Apply postoperative analgesia according to the specific animal protocol at your institution.
tumor growth and monitoring • tIMInG 4-8 weeks 43| Closely monitor the mice for tumor progression and continue to assess their health.
44|
At appropriate time points (e.g., 7-10 d after implantation, and then every 7 d afterward), an ultrasound device equipped with high-frequency ultrasound probes can be used to longitudinally assess tumor growth noninvasively under isoflurane anesthesia.
? trouBlesHootInG Troubleshooting advice can be found in table 1. 4 -induced liver fibrosis has been used for decades to study fibrogenesis in various mouse and rodent models of liver cirrhosis. Our protocol provides an orthotopic model of HCC in which tumor growth is modulated by the cirrhotic liver (Fig. 2) . The amount of fibrosis in the non-malignant liver tissue can be quantified by Masson's trichrome or Sirius red staining of fixed liver sections. An experienced liver pathologist should assess the staining and apply a semiquantitative score to determine the presence/absence of fibrosis and cirrhosis. In addition, staining for the hepatic stellate cell activation markers α-SMA, desmin or glial fibrillary acidic protein (GFAP) and collagen I will provide quantitative measures of fibrosis 7, 19 . Once the administration of CCl 4 is stopped, a small degree of spontaneous fibrosis regression may occur. However, complete reversal of cirrhosis is usually not observed after a full course of 12 weeks of CCl 4 administration in mice. Regression of fibrosis would take up to 16 weeks. Thus, the liver microenvironment retains the pathological features of inflammation, fibrogenesis and angiogenesis within the time frame of 5-8 weeks in which HCCs are induced and treatment is administered. The HCA-1 model also results in abundant angiogenesis and reproducible spontaneous lung metastases 11 (Fig. 4) . Thus, this model can be used to study HCC angiogenesis and metastasis. Evaluation of lung metastases should be based on both morphology and immunohistochemistry to confirm the expression of typical HCC markers (i.e., for α-fetoprotein). As there are multiple primary tumors in Stk-mutant mice and multiple nodules in lung metastasis from HCA-1 primary tumor grafts, both the number of nodules and their size should be used for quantification of tumor burden. In addition, these models show adaptive resistance to sorafenib-a standard therapy for advanced HCC-thus allowing studies of treatment resistance mechanisms. For example, we found upregulated fibrogenesis (collagen I depositions and extracellular matrix accumulation), higher levels of proinflammatory cytokines (such as CXCL12/SDF1-α) and hypoxia (as indicated by CA9 expression) in cirrhotic (CCl 4 -induced) livers compared with healthy control livers 7 . Furthermore, we observed that HCA-1 tumor growth was facilitated when the cells were implanted into a cirrhotic liver as compared with a healthy liver 11 (Fig. 5) . Moreover, the tumor growth delay after sorafenib was not as pronounced in syngeneic C3H mice with underlying liver cirrhosis 7, 11 . On the basis of our experience, essentially all 
